

8-9-06

09/718,725

SPM 1647

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Boyle, et al.

Serial No.: 09/718,725

Group Art Unit No.: 1647

Filed: November 22, 2000

Examiner: Deberry, Regina M.

For: OSTEOPROTEGERIN

Docket No.: A-378CIP2C3

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Under the guidelines of 37 C.F.R. 1.97, applicants submit a copy of each of the references listed on the attached supplemental PTO-1449 Modified form for consideration by the Examiner.


Applicants make no determination of relevancy with respect to the references submitted herewith and request the Examiner to make an independent determination of relevance and/or materiality of the references.

Applicants, by the undersigned attorney/agent, certify that each item contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months pursuant to 37 C.F.R. 1.97(e)(1) prior to the filing of this statement.

Applicants request consideration of this information and passage of the application to issue.

The Commissioner is hereby authorized to charge any additional fees which may be required or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen Inc. An original and one copy of this paper are enclosed.

Respectfully submitted,


Robert B. Winter
Attorney/Agent for Applicant(s)
Registration No.: 34,458
Phone: (805) 447-2425
Date: August 7, 2006

Please send all future correspondence to:

U.S. Patent Operations/ RBW
Dept. 4300, M/S 28-2-C
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1799


EXPRESS MAIL CERTIFICATE


"Express Mail" mail labeling number: EL 732825723 US

Date of Deposit: August 7, 2006

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to Mail Stop, the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


Dee Dee Sutherland
Printed Name


Signature



Sheet 1 Of 1

Modified Form PTO-1449

Atty. Docket No.

A-378CIP2C3

Serial No.

09/718,725

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Boyle, et al.

Filing Date

Nov. 22, 2000

Group

1647

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS		PUBLICATION NUMBER AND APPLICATION NUMBER	PUBLICATION DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
	A1						
	A2						
	A3						
	A4						
	A5						
	A6						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
							YES	NO
/RMD/	B1	WO 94/21670	29 Sep 1994	PCT				
/RMD/	B2	WO 96/28546	19 Sep 1996	PCT				
	B3							
	B4							
	B5							

OTHER DOCUMENTS (Including Publisher, Author, Title, Date, Pertinent Pages, Etc.)

/RMD/	C1	Abbas et al., Cellular and Molecular Immunology, pages 47-48, Second Edition. W.B. Saunders Company, Philadelphia (1994).
	C2	Alexander et al., "Altering the Antigenicity of Proteins", :Pro. Natl. Acad. Sci., 89, 3352-3356 (1992).
	C3	Garcia et al., "Transgenic Mice Expressing High Levels of Soluble TNF-R1 Fusion Protein are Protected from Lethal Septic Shock and Cerebral Malaria, and are Highly Sensitive to Listeria Monocytogenes and Leishmania Major Infections", Eur. J. Immunol, 25, 2401-2407 (1995).
	C4	Himmeler et al., "Molecular Cloning and Expression of Human and Rat Tumor Necrosis Factor Receptor Chain (p60) and Its Soluble Derivative, Tumor Necrosis Factor-Binding Protein", DNA and Cell Biology, 9(10), 705-715 (1990).
	C5	Ngo et al., Computational Complexity Protein Structure Prediction, and the Levinthal Paradox, The Protein Folding Problem and Tertiary Structure Prediction, pages 433-440 and 492-495. Merz and Le Grand, Editors, (Birkhauser Boston 1994)
/RMD/	C6	Wells, James A., "Additivity of Mutational Effects in Proteins", Biochemistry, 29(37) 8509-8517 (1990).

EXAMINER: /Regina DeBerry/ (07/31/2008)

Date Considered:

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.